{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:55:42Z","timestamp":1791813342411,"version":"4.3.4"},"reference-count":38,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.3892\/or.2015.3947","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T12:15:04Z","timestamp":1430828104000},"page":"407-414","source":"Crossref","is-referenced-by-count":10,"title":["Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma"],"prefix":"10.3892","volume":"34","author":[{"given":"YING","family":"YU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAOSU","family":"ZHAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YU","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YANLING","family":"KANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIAQI","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YINGCHUN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"key":"key20180107212423_b1-or-34-01-0407","first-page":"136","article-title":"Hepatoblastoma","volume":"11","author":"Stocker","year":"1994","journal-title":"Semin Diagn Pathol"},{"key":"key20180107212423_b2-or-34-01-0407","first-page":"576","article-title":"Hepatic rhabdomyosarcoma in an adult: A rare primary malignant liver tumor. Case report and literature review","volume":"74","author":"Schoofs","year":"2011","journal-title":"Acta Gastroenterol Belg"},{"key":"key20180107212423_b3-or-34-01-0407","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MOP.0000000000000046","article-title":"Hepatoblastoma state of the art: Pathology, genetics, risk stratification, and chemotherapy","volume":"26","author":"Czauderna","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"key20180107212423_b4-or-34-01-0407","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jpedsurg.2004.05.020","article-title":"Hepatoblastoma - evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases","volume":"39","author":"Davies","year":"2004","journal-title":"J Pediatr Surg"},{"key":"key20180107212423_b5-or-34-01-0407","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MPH.0000000000000072","article-title":"Single-agent cisplatin treatment of children with high-risk hepatoblastoma","volume":"36","author":"Zhang","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20180107212423_b6-or-34-01-0407","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(13)70300-0","article-title":"Dose-intensive cisplatin for hepatoblastoma: Have you heard?","volume":"14","author":"Qayed","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20180107212423_b7-or-34-01-0407","doi-asserted-by":"crossref","first-page":"33450","DOI":"10.1074\/jbc.C600164200","article-title":"Separating the anti-apoptotic and mitotic roles of survivin","volume":"281","author":"Colnaghi","year":"2006","journal-title":"J Biol Chem"},{"key":"key20180107212423_b8-or-34-01-0407","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrc968","article-title":"Validating survivin as a cancer therapeutic target","volume":"3","author":"Altieri","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key20180107212423_b9-or-34-01-0407","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","article-title":"Survivin: A promising tumor biomarker","volume":"249","author":"Duffy","year":"2007","journal-title":"Cancer Lett"},{"key":"key20180107212423_b10-or-34-01-0407","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"key":"key20180107212423_b11-or-34-01-0407","first-page":"89","article-title":"Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line","volume":"37","author":"Asechi","year":"2010","journal-title":"Int J Oncol"},{"key":"key20180107212423_b12-or-34-01-0407","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1476-5586(04)80051-4","article-title":"Upregulation of survivin in G2\/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis","volume":"6","author":"Chandele","year":"2004","journal-title":"Neoplasia"},{"key":"key20180107212423_b13-or-34-01-0407","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/0008-5472.CAN-05-3248","article-title":"Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells","volume":"66","author":"Tirro","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107212423_b14-or-34-01-0407","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"key20180107212423_b15-or-34-01-0407","first-page":"4313","article-title":"siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells","volume":"32","author":"Kunze","year":"2012","journal-title":"Anticancer Res"},{"key":"key20180107212423_b16-or-34-01-0407","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.20232","article-title":"Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo","volume":"65","author":"Hayashi","year":"2005","journal-title":"Prostate"},{"key":"key20180107212423_b17-or-34-01-0407","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107212423_b18-or-34-01-0407","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejpb.2014.06.015","article-title":"Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant","volume":"88","author":"Kawano","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"key20180107212423_b19-or-34-01-0407","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci"},{"key":"key20180107212423_b20-or-34-01-0407","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/dmd.108.025254","article-title":"Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells","volume":"37","author":"Minematsu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key20180107212423_b21-or-34-01-0407","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.leukres.2010.11.016","article-title":"Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma","volume":"35","author":"Kita","year":"2011","journal-title":"Leuk Res"},{"key":"key20180107212423_b22-or-34-01-0407","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdr353","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer","volume":"23","author":"Tolcher","year":"2012","journal-title":"Ann Oncol"},{"key":"key20180107212423_b23-or-34-01-0407","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107212423_b24-or-34-01-0407","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10637-009-9333-6","article-title":"A multicenter phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma","volume":"29","author":"Lewis","year":"2011","journal-title":"Invest New Drugs"},{"key":"key20180107212423_b25-or-34-01-0407","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","article-title":"YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels","volume":"11","author":"Kumar","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key20180107212423_b26-or-34-01-0407","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/mmr.2014.2729","article-title":"Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"key":"key20180107212423_b27-or-34-01-0407","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1248\/bpb.28.565","article-title":"Significance of survivin mRNA expression in prognosis of neuroblastoma","volume":"28","author":"Ito","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"key20180107212423_b28-or-34-01-0407","first-page":"360","article-title":"Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients","volume":"95","author":"Kappler","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180107212423_b29-or-34-01-0407","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0033-1333637","article-title":"Increased expression of survivin in hepatoblastoma after chemotherapy","volume":"23","author":"Uehara","year":"2013","journal-title":"Eur J Pediatr Surg"},{"key":"key20180107212423_b30-or-34-01-0407","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics","volume":"14","author":"Mita","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107212423_b31-or-34-01-0407","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","article-title":"Survivin: A new target for anti-cancer therapy","volume":"35","author":"Ryan","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"key20180107212423_b32-or-34-01-0407","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CAD.0b013e328344ac68","article-title":"YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model","volume":"22","author":"Nakahara","year":"2011","journal-title":"Anticancer Drugs"},{"key":"key20180107212423_b33-or-34-01-0407","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1158\/1078-0432.CCR-13-2707","article-title":"Combination of YM155, a survivin suppressant, with bendamustine and rituximab: A new combination therapy to treat relapsed\/refractory diffuse large B-cell lymphoma","volume":"20","author":"Kaneko","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20180107212423_b34-or-34-01-0407","first-page":"2909","article-title":"Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells","volume":"17","author":"Liang","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20180107212423_b35-or-34-01-0407","first-page":"5315","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Cancer Res"},{"key":"key20180107212423_b36-or-34-01-0407","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","article-title":"Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models","volume":"17","author":"Yamanaka","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107212423_b37-or-34-01-0407","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1566524014666140128111951","article-title":"Caspase-8 as a regulator of tumor cell motility","volume":"14","author":"Graf","year":"2014","journal-title":"Curr Mol Med"},{"key":"key20180107212423_b38-or-34-01-0407","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbrc.2013.04.036","article-title":"YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells","volume":"435","author":"Feng","year":"2013","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.3947\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:24:36Z","timestamp":1515360276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.3947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,5,5]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3892\/or.2015.3947"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.3947","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]}}}